Anthony Bergmann

CFO Anthony Bergmann sells 24,100 CAPR shares at $30.38; stock down 41.0% from 52-week high, now $23.80

Anthony Bergmann, Chief Financial Officer, sold 24,100 shares of CAPRICOR THERAPEUTICS at $30.38 on 2026-06-25, reducing his non-derivative holdings from 35,323 shares to 11,223 shares. The sale occurred as CAPR trades at $23.80, down 41.0% from its 52-week high of $40.37, and the stock has declined 20.6% over the prior 30 days and 21.7% over the prior 90 days. Fundamentals remain challenging: the company reported quarterly revenue of $2,261,642.00 with net income of $-33,941,345.00, annual revenue growth of -100.0%, and the company remains unprofitable. Notably, Bergmann retains 91,980 shares in derivative securities (stock options), so his overall economic position in CAPR is not fully liquidated despite the substantial reduction in non-derivative shares.

CFO Bergmann executes same-day option exercise and full sale, harvesting gains while company burns cash with no revenue.

CFO Anthony Bergmann exercised options and immediately sold the entire position on the same day, converting an acquisition valued at roughly $80,000 into proceeds of approximately $793,000. This is Bergmann's second open-market sale at Capricor in six months, following a prior exit in late March where the stock subsequently rose—indicating poor timing on his previous exit. The current sale appears similarly timed: the stock is trading well below its 52-week high and has declined sharply over the past month, yet Bergmann's last sell did not precede that weakness. More concerning is the company's financial position: Capricor has zero annual revenue, a substantial net loss, and is burning cash while the stock remains above its 52-week low. The lack of any offsetting insider buying activity—despite the CFO's repeated selling—and the company's deteriorating fundamentals suggest Bergmann is reducing exposure rather than showing confidence in a near-term turnaround.

CFO Bergmann sold 25,000 shares (75.2% of holdings) at $30.13; company posted -$24.6M net income on $2.3M revenue

Anthony Bergmann, CFO of Capricor Therapeutics, divested 25,000 shares worth $753,152.50 on March 31, 2026, reducing his holdings from 33,223 shares to 8,223 shares—a 75.2% reduction. This substantial stake reduction is particularly noteworthy given the company's fundamental position: latest-quarter revenue of $2,261,642.00 sits against a net loss of $24,570,647.00, and annual revenue growth is -100.0%, indicating a dramatic contraction. The CFO's near-total exit of his position occurs at $30.13 per share, near the current price of $30.12 but well below the 52-week high of $33.57, suggesting the sale was not executed at peak valuation. For a company in deep negative profitability and declining revenue, the CFO's substantial liquidation underscores the severity of the operational challenges investors are facing.